CytomX Therapeutics (CTMX) Operating Income (2014 - 2026)

CytomX Therapeutics has reported Operating Income for 13 years, with the latest figure at -$19.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 186.96% year-over-year to -$19.7 million; the trailing twelve-month figure through Mar 2026 stood at -$45.9 million (down 227.62% YoY), and the FY2025 full-year result was -$3.6 million, down 114.39% from the prior year.
• Operating Income for Q1 2026 stood at -$19.7 million, down from -$9.2 million in the prior quarter.
• The five-year high for Operating Income was $22.6 million in Q1 2025, with the low at -$32.1 million in Q1 2022.
• Historically, Operating Income has averaged -$6.2 million across 5 years, with a median of -$5.7 million in 2023.
• Annual changes were most pronounced in 2024 — Operating Income surged 3017.33% — and 2025, when it tumbled 483.56%.
• CytomX Therapeutics' Operating Income stood at -$9.5 million in 2022, then jumped by 93.63% to -$606000.0 in 2023, then surged by 3017.33% to $17.7 million in 2024, then tumbled by 151.85% to -$9.2 million in 2025, then plunged by 114.62% to -$19.7 million in 2026.
• The last three Operating Income figures came in at -$19.7 million (Q1 2026), -$9.2 million (Q4 2025), and -$15.8 million (Q3 2025), per Business Quant data.